In the lab

Our team is focused on expanding the applications and continuing the research and development of Nanovega technology. The unique capabilities of Nano-Antibodies bring great hope to cancer research, diagnostics, and eventually therapeutics with a technology that is safer, more effective, and less costly than current antibody-based technologies. We are committed to bringing this exciting tool to the scientists and healthcare professionals who make a difference in our lives.


  • American Human Genetics Society
  • American Protein Society
  • American Antibody Society
  • American Medical Association
  • American Society for Clinical Chemistry
  • Wisconsin Alumni Research Foundation
  • Wisconsin Medical Foundation
  • American Society for Clinical Oncology

Marek Malecki MD PhD

Telephone: 415-640-9300
Fax: 415-640-9303
Skype: President_Nanovega

Dr. Marek Malecki is the Founder, Chairman and President of Nanovega, Inc.

Dr. Malecki is currently the Principal Investigator of a project for the National Institutes of Health entitled “Engineering of Antibodies” and a Visiting Professor at the University of Wisconsin. He is the former Project Coordinator for the National Institutes of Health National Biotechnology Resource and former Director of the Molecular Imaging Laboratories at the University of California, San Diego.

Dr. Malecki is also currently the Editor in Chief for several peer-reviewed scientific journals including the Journal of Genetic Syndromes & Gene Therapy, the Journal of Stem Cell Research & Therapy and the Journal of Regenerative Medicine. He is also an Editorial Board Member for the peer-reviewed scientific journals Frontiers: Genetics, Journal of Molecular and Cell Therapy – Regenerative Medicine and the Journal of Cancer Research and Therapy. Dr. Malecki has also authored numerous peer-reviewed scientific publications which have been published in a number of highly regarded scientific journals.

Dr. Malecki is currently the inventor of Nano-Antibodies which are protected by six patent applications pending at the USPTO and WIPO. He is also the member of a number of Professional Societies including the AMA, ASHG, APS, SCBC and Rho Phi Society for Excellence in Teaching and Faculty Role Models.

Randy Berholtz JD

Chief Executive Officer
Telephone: 858-205-5091
Fax: 858-205-5092
Skype: CEO_Nanovega

Randy Berholtz is the Chief Executive Officer and a member of the Board of Directors of Nanovega, Inc.

He is a longtime executive and attorney for companies in the life science, venture capital and legal industries.He has held executive positions with Apricus Biosciences, Inc., a public pharmaceutical company (Nasdaq), the ACON Group, a group of private Chinese and US life science companies, IngleWood Ventures, L.P., a San Diego-based life sciences venture fund and Nanogen, Inc., a public genomics tools company (Nasdaq).

He currently serves on the Board of Directors of Strategic Drug Solutions, Inc., a biopharmaceutical company, is a consultant to Innovus Pharmaceuticals, Inc., a pharmaceutical company and is on the Advisory Council of the Keck Graduate Institute of Applied Sciences at the Claremont Colleges (“KGI”). He was previously on the board of directors of four other life science companies.

He is also an Adjunct Professor of Law at the Thomas Jefferson School of Law and has also taught biotechnology law, patent law, patent litigation and business law at the University of San Diego School of Law, the Rady School of Business at the university of California, San Diego and at KGI. He has also worked for the law firms of Heller Ehrman, LLP, Cooley Godward, LLP, Kirkpatrick & Lockhart, LLP (now K&L Gates) and Cravath, Swaine & Moore, LLP.He is a graduate of Cornell University, Oxford University where he was a Rhodes Scholar and the Yale Law School.

John Langmore PhD

James Hainfeld PhD

Patrizia Paterlini MD PhD

For pricing information contact us:
fluorescent at 619nm
superparamagnetic at 0.4 - 11T
x-ray opaque at 10 - 150keV
HTFR fluorescent at 619nm
HEGFR fluorescent at 619nm
HEGFR2 fluorescent at 619nm
HEGFRvIII fluorescent